Next Article in Journal
In Vivo Anti-Leukemia, Quantum Chemical Calculations and ADMET Investigations of Some Quaternary and Isothiouronium Surfactants
Next Article in Special Issue
Calcium Channel Blockers as Tocolytics: Principles of Their Actions, Adverse Effects and Therapeutic Combinations
Previous Article in Journal
Improved Estimation of Protein-Ligand Binding Free Energy by Using the Ligand-Entropy and Mobility of Water Molecules
Previous Article in Special Issue
Clevidipine for Perioperative Blood Pressure Control in Infants and Children
Pharmaceuticals 2013, 6(5), 623-633; doi:10.3390/ph6050623

In Vitro Assessment of Clevidipine Using the Profilin1 Hypertensive Mouse Model

1,†,* , 2,†
Received: 21 December 2012 / Accepted: 19 April 2013 / Published: 29 April 2013
(This article belongs to the Special Issue Calcium Antagonists)
View Full-Text   |   Download PDF [367 KB, uploaded 29 April 2013]   |   Browse Figures


Hypertension represents a major risk factor for cardiovascular events, associating with vascular hypertrophy and dysfunction in resistance vessels. Clevidipine is a novel antihypertensive drug working as a selective calcium channel antagonist with an ultra-short half-life that lowers arterial blood pressure by reducing systemic arterial resistance. The aim was to assess the effect of clevidipine on the hypertrophic vessels of profilin1 hypertensive transgenic mice compared to sodium nitroprusside (SNP) and labetalol using wire myograph techniques. The effects of clevidipine, SNP and labetalol on the hypertrophic vessels were studied on mesenteric arterial function from 8 profilin1 hypertrophic mice and eight non-transgenic controls. Our results showed a significant difference between the effects of the three drugs on the hypertrophic mesenteric arteries of transgenic profilin1 mice compared to the non-transgenic controls. The half maximal effective concentration (EC50) of clevidipine, SNP and labetalol in profilin1 mice (1.90 ± 0.05, 0.97 ± 0.07, 2.80 ± 0.05 nM, respectively) were significantly higher than the EC50 in non-transgenic controls (0.91 ± 0.06, 0.32 ± 0.06, 0.80 ± 0.09 nM, respectively). Moreover, the increase in the EC50 for clevidipine (2-fold) to produce the same effect on both normal and hypertrophic arteries was less than that of SNP (3-fold) and labetalol (3.5-fold). Therefore, we concluded clevidipine exhibited the lowest dose shift to relax the hypertrophic vessels compared to SNP and labetalol in the profilin1 hypertrophic animal mouse model.
Keywords: clevidipine; transgenic profilin1 mice; vascular hypertrophy; wire-myograph clevidipine; transgenic profilin1 mice; vascular hypertrophy; wire-myograph
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Hassanain, H.H.; Hassona, M.D.H.; Puente, E.G.; Sun, C.; Abouelnaga, Z.A.; Tulman, D.B.; Bergese, S.D. In Vitro Assessment of Clevidipine Using the Profilin1 Hypertensive Mouse Model. Pharmaceuticals 2013, 6, 623-633.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert